Skip to Content

Uptravi FDA Approval History

FDA Approved: Yes (First approved December 21, 2015)
Brand name: Uptravi
Generic name: selexipag
Dosage form: Tablets
Company: Actelion Pharmaceuticals US, Inc.
Treatment for: Pulmonary Hypertension

Uptravi (selexipag) is an oral prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension.

Development Timeline for Uptravi

Dec 22, 2015Approval FDA Approves Uptravi (selexipag) for Pulmonary Arterial Hypertension
Mar  3, 2015Actelion's NDA for Selexipag (Uptravi) Accepted by the FDA
Dec 23, 2014Actelion Submits NDA for Selexipag (Uptravi) in Patients with Pulmonary Arterial Hypertension

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.